Loading...
Cefpodoxime Dry Syp
A premium, dual-action antibacterial dry syrup designed for the intensive management of resistant pediatric infections. EXLLA-CV combines a powerful third-generation cephalosporin with a beta-lactamase inhibitor to ensure clinical success against "tough" bacteria that have developed defenses against standard antibiotics.
A premium, dual-action antibacterial dry syrup designed for the intensive management of resistant pediatric infections. EXLLA-CV combines a powerful third-generation cephalosporin with a beta-lactamase inhibitor to ensure clinical success against "tough" bacteria that have developed defenses against standard antibiotics.
EXLLA-CV utilizes the powerful combination of Cefpodoxime and Potassium Clavulanate. While Cefpodoxime works to destroy the bacterial cell wall, Clavulanate acts as a sterile shield, neutralizing the beta-lactamase enzymes that bacteria produce to protect themselves. This synergy ensures that the antibiotic remains 100% effective even against highly resistant strains.
Cefpodoxime is a broad-spectrum cephalosporin known for its superior tissue penetration. It is highly effective against a wide range of pathogens responsible for respiratory, ear, and urinary tract infections, providing a faster onset of action and a higher clinical cure rate compared to older generations of antibiotics.
This formulation is specifically engineered for children who suffer from recurrent infections or cases where previous antibiotic treatments have failed. By overcoming bacterial resistance, EXLLA-CV prevents the progression of the disease and reduces the risk of complications such as chronic sinusitis or secondary pneumonia.
The dry syrup format preserves the potency of the active ingredients until the moment of use. Once reconstituted, it ensures rapid absorption into the bloodstream, reaching the site of infection quickly to reduce high-grade fever and localized inflammation within the first few doses.
EXLLA-CV provides a robust defense against a wide array of Gram-positive and Gram-negative bacteria, including resistant H. influenzae and Moraxella catarrhalis. This makes it a gold-standard choice for treating complicated middle ear infections (Otitis Media) and community-acquired pneumonia in children.
The balanced ratio of Cefpodoxime to Clavulanate is designed to maximize bactericidal impact while maintaining excellent gastrointestinal tolerability. The pleasant-tasting syrup ensures better compliance from pediatric patients, making the full course of treatment easier for parents to administer.
Indication Resistant Acute Otitis Media (Ear Infection), Recurrent Tonsillitis and Sinusitis, Community-Acquired Pneumonia, Complicated Urinary Tract Infections (UTIs), Skin and Soft Tissue Infections, Typhoid Fever and Respiratory Flare-ups.
Product descriptions, dosage forms, and compositions listed on the website are for reference by licensed practitioners and distributors only.
Amoxycillin Trihydrate 400g+ Clavulanic Acid 57mg
Amoxycillin 200 mg +Potassium Clavulanic 28.5 mg+ Lactic Acid Bacillus 60 Million Spores
